Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2002
12/12/2002US20020187499 Kit for use in monitoring and treatment of endometriosis
12/12/2002US20020187495 Genetic polymorphisms of estrogen receptor alpha associated with favorable HDL cholesterol response to hormone replacement therapy
12/12/2002US20020187491 Beta-adrenoceptor genetic polymorphisms and obesity
12/12/2002US20020187472 Nucleotide sequences coding protein for use in the treatment of cancer
12/12/2002US20020187247 Branched maltodextrins having between 15 and 35% of 1-6 glucoside linkages, a reducing sugar content of less than 20%, a polymolecularity index of less than 5
12/12/2002US20020187235 Ingestible laxative beverage
12/12/2002US20020187219 A) one or more flavanols; b) one or more bracers such as caffeine; and c) vitamin B
12/12/2002US20020187209 Anti-ulcer pharmaceutical composition and the preparation thereof
12/12/2002US20020187204 Diet composition and method of weight management
12/12/2002US20020187193 E.g., 7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6 -fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid; treatment of ocular and periocular infections.
12/12/2002US20020187192 Pharmaceutical composition which reduces or eliminates drug abuse potential
12/12/2002US20020187191 Oxidized collagen formulations for use with non-compatible pharmaceutical agents
12/12/2002US20020187189 Proliposomal drug delivery system
12/12/2002US20020187187 Fast disintegrating meloxicam tablet
12/12/2002US20020187186 Pharmaceutical tablets
12/12/2002US20020187184 Method of treating restenosis using bisphosphonate nanoparticles
12/12/2002US20020187181 System for delivering cosmetics and pharmaceuticals
12/12/2002US20020187180 Adding a sulfated polysaccharide component, such as a carrageenan compound
12/12/2002US20020187179 Non-steroidal anabolic compositions and associated methods
12/12/2002US20020187171 Composition for solubilizing salicylic acid
12/12/2002US20020187169 Kavalactone compositions
12/12/2002US20020187165 Composition for female sexual arousal
12/12/2002US20020187155 Ringworm vaccine
12/12/2002US20020187152 Administering a drug which can selectively kill Fusobacterium varium cells, or a drug which can neutralize the toxin produced by Fusobacterium varium cells; vaccines, diagnosis, screening
12/12/2002US20020187149 Activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptible carrier.
12/12/2002US20020187137 S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
12/12/2002US20020187135 Methods for inducing antigen-specific t cell tolerance
12/12/2002US20020187134 Prebiotic and probiotic compositions and methods for their use in gut-based therapies
12/12/2002US20020187130 Simultaneously stimulate response in white blood cells and a patient's tumor cells with a mitogen-challenging compound, especially a phytohemagglutinin, and to generate heat shock protein.
12/12/2002US20020187121 Administering an amine polymer, such as a polyethylenimine salt or an epichlorohydrin crosslinked polyallylamine
12/12/2002US20020187120 Method for treating gout and reducing serum uric acid
12/12/2002US20020187118 Shaving preparations and methods for the prevention and treatment of pseudofolliculitis barbae
12/12/2002US20020187105 Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
12/12/2002US20020187102 Novel compositions for use in embolizing blood vessels
12/12/2002US20020187068 Method of inactivating pathogens
12/12/2002US20020185558 Method of milling pharmaceutical preparation
12/12/2002DE10127717A1 Cosmetic or dermatological preparations for combating undesirable skin pigmentation, e.g. in treatment of local hyperpigmentation disorders or cosmetic inhibition of tanning, containing pyridoxine as active agent
12/12/2002DE10127544A1 Photodynamic therapy used for killing tumor cells in humans, by application of light in presence of carbonyl-substituted chlorin compound as oxidation stable photosensitizer
12/12/2002DE10126501A1 Composition used for detaching abnormal keratin material e.g. warts or fungally damage nails, comprises mixture of urea, film former and water or aqueous alcohol
12/12/2002DE10125883A1 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie Medicines containing an effector of the glutathione metabolism together with alpha-lipoic acid in the context of renal replacement therapy
12/12/2002DE10125882A1 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Behandlung des Diabetes mellitus Medicines containing an effector of the glutathione metabolism together with alpha-lipoic acid in the treatment of diabetes mellitus
12/12/2002DE10124953A1 Active agent used for treating acute or chronic tinnitus comprises stimulant of brain-derived nerve growth factor gene exons III and IV e.g. kainate
12/12/2002DE10065413A1 Zahnpflegemittel Dentifrice
12/12/2002CA2450009A1 Method and apparatus for treating tumors using low strength electric fields
12/12/2002CA2449940A1 Bcl-2 dnazymes
12/12/2002CA2449877A1 Tetramerous derivative of indole-3-carbinol with anti-carcinogenic activity and method of synthesis of said derivative
12/12/2002CA2449843A1 Non-peptide gnrh agents, pharmaceutical compositions and methods for their use, and processes for preparing them
12/12/2002CA2449842A1 Zinc containing compositions for anti-viral use
12/12/2002CA2449825A1 Use of an antioxidant for treating and/or preventing surface ocular disorders
12/12/2002CA2449814A1 Methods and kits for diagnosing a pancreatic-based fat malabsorption disorder
12/12/2002CA2449813A1 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
12/12/2002CA2449771A1 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
12/12/2002CA2449770A1 Novel anti-infectives
12/12/2002CA2449712A1 Method for reducing muscle fatigue through administration of adenosine triphosphate
12/12/2002CA2449671A1 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
12/12/2002CA2449658A1 Use of rank antagonists to treat cancer
12/12/2002CA2449482A1 Chds as modifiers of the p53 pathway and methods of use
12/12/2002CA2449450A1 Cancer treatment method and compositions comprising compounds of the ginger family
12/12/2002CA2449425A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002CA2449316A1 Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy
12/12/2002CA2449289A1 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002CA2449281A1 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002CA2449275A1 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002CA2449270A1 Pibs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449267A1 Hs2sts as modifiers of the p53 pathway and methods of use
12/12/2002CA2449221A1 P5crs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449206A1 Cads as modifiers of the p53 pathway and methods of use
12/12/2002CA2449175A1 Use of methylnaltrexone to treat immune suppression
12/12/2002CA2449136A1 Igs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449109A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002CA2449103A1 Topical compositions for veterinary uses
12/12/2002CA2449097A1 5-ethyl-imidazotriazinones
12/12/2002CA2449095A1 Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases
12/12/2002CA2449077A1 Epothilone derivatives
12/12/2002CA2449024A1 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
12/12/2002CA2449021A1 Novel compounds and compositions as cathepsin inhibitors
12/12/2002CA2448834A1 Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
12/12/2002CA2448828A1 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2
12/12/2002CA2448665A1 Sustained-release analgesic compounds
12/12/2002CA2448656A1 Compositions and methods for inhibiting bone resorption
12/12/2002CA2448444A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
12/12/2002CA2448418A1 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
12/12/2002CA2448384A1 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent
12/12/2002CA2448379A1 Calorically dense liquid oral supplement
12/12/2002CA2448282A1 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002CA2448250A1 Limks as modifiers of the p53 pathway and methods of use
12/12/2002CA2448107A1 Marks as modifiers of the p53 pathway and methods of use
12/12/2002CA2448044A1 Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof
12/12/2002CA2448040A1 Antimycotic agent
12/12/2002CA2447746A1 Cycloalkenylsulfonamide derivatives
12/12/2002CA2447732A1 Antineoplastic combinations
12/12/2002CA2447480A1 Pyranoindazoles and their use for the treatment of glaucoma
12/12/2002CA2447479A1 Novel arylaminopropane analogues and their use for the treatment of glaucoma
12/12/2002CA2447156A1 Novel fused indazoles and indoles and their use for the treatment of glaucoma
12/12/2002CA2447111A1 Solutions of alkoxylated alkanol amide surfactants and antimicrobial compounds
12/12/2002CA2446719A1 Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
12/12/2002CA2446716A1 Sulfonamide derivatives
12/12/2002CA2446696A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
12/12/2002CA2446160A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug
12/12/2002CA2445460A1 Carboline derivatives as pde-5 inhibitors
1 ... 5623 5624 5625 5626 5627 5628 5629 5630 5631 5632 5633 5634 5635 5636 5637 5638 5639 5640 5641 5642 5643 ... 7860